Alzheimer's Disease Study is looking for people aged 18-80 who might carry a gene mutation linked to early-onset Alzheimer’s. The study aims to find out if certain drugs can slow down or change the progression of the disease. Participants will undergo tests like brain scans (MRI and PET) and provide blood and spinal fluid samples. The study lasts up to four years, with an option for extra treatment afterward. You don’t have to know if you carry the gene to join, and some participants will receive a placebo (a harmless pill with no effect) instead of the study drug. This helps researchers compare results. The study is double-blinded, meaning neither you nor the researchers will know if you're receiving the study drug or placebo, ensuring fair results.

Here are some key points to consider:

• The study requires frequent visits for tests and assessments over four years.
• You may receive compensation for your participation.
• There is a possibility of receiving a placebo instead of the active drug.